Belzutifan: First Approval-Reference-Cited by-同舟云学术

Belzutifan: First Approval

Published:2021-10-06 Issue:16 Volume:81 Page:1921-1927
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Deeks Emma D.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-021-01606-x.pdf

Reference19 articles.

1. Chung C. From oxygen sensing to angiogenesis: targeting the hypoxia signaling pathway in metastatic kidney cancer. Am J Health Syst Pharm. 2020;77(24):2064–73.

2. Yu Y, Yu Q, Zhang X. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma. Drug Discov Today. 2019;24(12):2332–40.

3. Schonberger T, Fandrey J, Prost-Fingerle K. Ways into understanding HIF inhibition. Cancers. 2021;13(1):1–16.

4. Merck Sharp & Dohme Corp. Welireg™ (belzutifan) tablets, for oral use: US prescribing information. 2021. https://www.accessdata.fda.gov/. Accessed 24 Aug 2021.

5. National Organization for Rare Disorders. Von Hippel-Lindau disease. 2021. https://rarediseases.org/rare-diseases/von-hippel-lindau-disease/. Accessed 24 Aug 2021.

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia-driven heterogeneous expression of α5 integrin in glioblastoma stem cells is linked to HIF-2α;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. FDA approved fluorine-containing drugs in 2023;Chinese Chemical Letters;2024-11

3. Neurosurgical Implications of Targeting Hypoxia-Inducible Factor 2α in Hemangioblastomas with Belzutifan;World Neurosurgery;2024-10

4. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications;European Journal of Medicinal Chemistry;2024-10

5. Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice;JCO Precision Oncology;2024-09